



**The Executive Office of Health & Human Services
Center for Operations and Pharmacy Management**

Pharmacy and Therapeutics Committee Meeting Minutes

Tuesday, April 4, 2017

8:00 AM

HP Enterprise Services

301 Metro Center Blvd, Room 203

Warwick, Rhode Island 02886

P & T Members Present: Scott Campbell, RPh
Dave Feeney, RPh, Chairperson
Rita Marcoux RPh, Co-Chairperson
Matt Salisbury, MD
Richard Wagner, MD

P & T Members Absent: Greg Allen, MD
Kristina Ward, PharmD

Others Present: Jerry Fingerut, MD (Conduent)
Karen Mariano, RPh (DXC Technology)
Kathryn Novak, RPh, MBA (Magellan Medicaid Administration)

**The meeting was called to order by the Chairperson once a quorum was in attendance - 8:10 am.
The December 2016 meeting minutes were reviewed and by vote were accepted as presented.**

Public testimony included the following speakers:

1. Cathy Mullooly, Novo Nordisk. Victoza, Tresiba, Norditropin
2. Mehak Talwar & Brian, Korenda, Boehringer Ingelheim. Jardiance
3. Tom Algozzine, Novartis. Gilyena
4. Jeff Olson, Gilead. Epclusa
5. Brian Calamari, Abbvie. Zinbryta

Magellan Medicaid Administration (MMA) presented the following categories for therapeutic class reviews with discussion from the pharmacy and therapeutics committee.

- a. Acne Agents. A motion was made and unanimously approved to accept the recommendations as presented.
- b. Analgesics, Narcotics Short. Motion made, and discussion on the motion. Concern about combination products/single ingredients. Recommendations include a single ingredient item. Request that PDL include footnote regarding legislation limiting quantities when prescribing opioids for acute pain. A motion was made and unanimously approved to accept the recommendations as presented.
- c. Analgesics, Narcotics Long. Motion made, and discussion on the motion. Request that the website include an annotation that these agents are not for acute therapy and all are on prior authorization. A motion was made and unanimously approved to accept the recommendations as presented.
- d. Antiemetics. Motion made, and discussion on the motion. Do other states have a duration limitation? Yes, some states have limits; including for antiemetic chemotherapy. A motion was made and unanimously approved to accept the recommendations as presented.
- e. Antihyperuricemics. A motion was made and unanimously approved to accept the recommendations as presented.
 - i. Antiviral Agents Oral.HSV Agents. A motion made and unanimously approved to accept the recommendations as presented.
 - ii. Influenza Agents. A motion made and discussion on the motion. Motion made to remove rimantidine and accept the rest of the recommendations.

- iii. Hepatitis C Agents. A motion made and discussion on the motion. Question; do the MCO's follow the FFS policy? Yes. Process in place to insure continuity of therapy for patients who transition between programs. A motion made and unanimously approved to accept the recommendations as presented.
- f. Antivirals, topical. A motion made and unanimously approved to accept the recommendations as presented.
- g. Bone Resorption Inhibitors. A motion made and discussion on the motion. Request the inclusion of a raloxifene product on the PDL. A motion made and unanimously approved to accept the recommendations as presented with the inclusion of a raloxifene product.
- h. Growth Hormones. A motion made and unanimously approved to accept the recommendations as presented.
- i. Hypoglycemics. Guideline updates; ADA, AACE/ACE, ACP
 - i. Alpha-glucosidase inhibitors. A motion made and unanimously approved to accept the recommendations as presented.
 - ii. Incretin mimetics/enhancers. A motion made and unanimously approved to accept the recommendations as presented.
 - iii. Insulins. A motion made and discussion on the motion. Discussion on the substitutability of biologics products. A motion made and unanimously approved to accept the recommendations as presented.
 - iv. Meglitinides. A motion made and unanimously approved to accept the recommendations as presented.
 - v. Metformins. A motion made and unanimously approved to accept the recommendations as presented.
 - vi. SGLT-2. A motion made and unanimously approved to accept the recommendations as presented.
 - vii. Sulfonylureas. A motion made and unanimously approved to accept the recommendations as presented.
 - viii. Thiazolidinediones. A motion made and unanimously approved to accept the recommendations as presented.
- j. Immunomodulators, atopic dermatitis. A motion made and unanimously approved to accept the recommendations as presented.
- k. Immunomodulators, topical. A motion made and unanimously approved to accept the recommendations as presented.
- l. Multiple Sclerosis Agents. Motion and discussion on the motion. A motion made and unanimously approved to accept the recommendations as presented.
- m. Pancreatic Enzymes. A motion made and unanimously approved to accept the recommendations as presented.
- n. H. Pylori Agents. A motion made and discussion on the motion. DUR committees across states look at utilization for appropriate prescribing. Find that states pay for individual agents not the combined products. A motion made and unanimously approved to accept the recommendations as presented.
- o. Proton Pump Inhibitors. A motion made and discussion on the motion. Have other State DUR boards looked at the duration of therapy? Request that the DUR board look at duration of therapy. A motion made and unanimously approved to accept the recommendations as presented.
- p. Psoriasis – Topical Agents. A motion made and unanimously approved to accept the recommendations as presented.
- q. Topical Steroids. A motion made and unanimously approved to accept the recommendations as presented.

Meeting Adjourned – 9:40am.

2017 Meeting Schedule – 8:00 am

June 13th

September 12th

December 12th